Lupus Atherosclerosis Prevention Study (LAPS)

Annals of the Rheumatic Diseases

Volumn 70, Issue 5, 2011, Pages 760-765

  Petri, Michelle A ^a   Kiani, A N ^a   Post, W ^a   Christopher Stine, L ^a   Magder, L S ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; PLACEBO;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTERY CALCIFICATION; ARTERY INTIMA; ARTICLE; CARDIOVASCULAR DISEASE; CELL ACTIVATION; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; ENDOTHELIUM CELL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MYASTHENIA GRAVIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; SYSTEMIC LUPUS ERYTHEMATOSUS; THYMUS HYPERPLASIA; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ATHEROSCLEROSIS; CAROTID ARTERY DISEASES; CORONARY ARTERY DISEASE; DOUBLE-BLIND METHOD; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PYRROLES; SEVERITY OF ILLNESS INDEX; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79953324124     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2010.136762     Document Type: Article

References (43)

1. Ward MM. Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum 1999;42:338-46. (Pubitemid 29072852)
2. Gladman DD, Urowitz MB. Morbidity in systemic lupus erythematosus. J Rheumatol Suppl 1987;14(Suppl 13):223-6.
3. Westerweel PE, Luyten RK, Koomans HA, et al. Premature atherosclerotic cardiovascular disease in systemic lupus erythematosus. Arthritis Rheum 2007;56:1384-96. (Pubitemid 46764065)
4. Petri M, Perez-Gutthann S, Spence D, et al. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med 1992;93:513-9.
5. Urowitz MB, Bookman AA, Koehler BE, et al. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med 1976;60:221-5.
6. Manzi S, Meilahn EN, Rairie JE, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997;145:408-15. (Pubitemid 27084212)
7. Esdaile JM, Abrahamowicz M, Grodzicky T, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001;44:2331-7. (Pubitemid 32977500)
8. Svenungsson E, Jensen-Urstad K, Heimbürger M, et al. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 2001;104:1887-93. (Pubitemid 32983229)
9. Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-43. (Pubitemid 30165206)
10. Asanuma Y, Oeser A, Shintani AK, et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003;349:2407-15. (Pubitemid 37542989)
11. Kiani AN, Magder L, Petri M. Coronary calcium in systemic lupus erythematosus is associated with traditional cardiovascular risk factors, but not with disease activity. J Rheumatol 2008;35:1300-6. (Pubitemid 352000774)
12. Manzi S, Kuller LH, Edmundowicz D, et al. Vascular imaging: changing the face of cardiovascular research. Lupus 2000;9:176-82. (Pubitemid 30199259)
13. Roman MJ, Shanker BA, Davis A, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003;349:2399-406. (Pubitemid 37542988)
14. Callister TQ, Raggi P, Cooil B, et al. Effect of HMG-CoA reductase inhibitors on coronary artery disease as assessed by electron-beam computed tomography. N Engl J Med 1998;339:1972-8. (Pubitemid 29024129)
15. Meroni PL, Luzzana C, Ventura D. Anti-inflammatory and immunomodulating properties of statins. An additional tool for the therapeutic approach of systemic autoimmune diseases? Clin Rev Allergy Immunol 2002;23:263-77.
16. Meroni PL, Raschi E, Testoni C, et al. Statins prevent endothelial cell activation induced by antiphospholipid (anti-beta2-glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype. Arthritis Rheum 2001;44:2870-8. (Pubitemid 34016207)
17. McCarey DW, McInnes IB, Madhok R, et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA):double-blind, randomised placebo-controlled trial. Lancet 2004;363:2015-21. (Pubitemid 38781100)
18. Paul F, Waiczies S, Wuerfel J, et al. Oral high-dose atorvastatin treatment in relapsing-remitting multiple sclerosis. PLoS ONE 2008;3:e1928.
19. Vollmer T, Key L, Durkalski V, et al. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 2004;363:1607-8. (Pubitemid 38625664)
20. Sena A, Pedrosa R, Morais MG. Statins for multiple sclerosis. Lancet 2004;364:412; author reply 412-3.
21. Costenbader KH, Liang MH, Chibnik LB, et al. A pravastatin dose-escalation study in systemic lupus erythematosus. Rheumatol Int 2007;27:1071-7. (Pubitemid 47246586)
22. Noël B, Panizzon RG. Lupus-like syndrome associated with statin therapy. Dermatology (Basel) 2004;208:276-7. (Pubitemid 38594552)
23. Ahmad A, Fletcher MT, Roy TM. Simvastatin-induced lupus-like syndrome. Tenn Med 2000;93:21-2.
24. Petri M, Kim MY, Kalunian KC, et al. OC-SELENA Trial. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005;353:2550-8. (Pubitemid 41785892)
25. Bots ML, Mulder PG, Hofman A, et al. Reproducibility of carotid vessel wall thickness measurements. The Rotterdam Study. J Clin Epidemiol 1994;47:921-30. (Pubitemid 24268897)
26. Smilde TJ, Wollersheim H, Van Langen H, et al. Reproducibility of ultrasonographic measurements of different carotid and femoral artery segments in healthy subjects and in patients with increased intima-media thickness. Clin Sci 1997;93:317-24. (Pubitemid 27464294)
27. Roman MJ, Crow MK, Lockshin MD, et al. Rate and determinants of progression of atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2007;56:3412-9. (Pubitemid 47585436)
28. Thompson T, Sutton-Tyrrell K, Wildman RP, et al. Progression of carotid intima-media thickness and plaque in women with systemic lupus erythematosus. Arthritis Rheum 2008;58:835-42. (Pubitemid 351364882)
29. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7. (Pubitemid 13221242)
30. Perez-Gutthann S, Petri M, Hochberg MC. Comparison of different methods of classifying patients with systemic lupus erythematosus. J Rheumatol 1991;18:1176-9.
31. Trager J, Ward MM. Mortality and causes of death in systemic lupus erythematosus. Curr Opin Rheumatol 2001;13:345-51. (Pubitemid 32929862)
32. Ridker PM, Rifai N, Clearfield M, et al. Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001;344:1959-65. (Pubitemid 32568149)
33. Ridker PM, Rifai N, Pfeffer MA, et al. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999;100:230-5. (Pubitemid 29340127)
34. Albert MA, Danielson E, Rifai N, et al. PRINCE Investigators. Effect of statin therapy on C-reactive protein levels:the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001;286:64-70.
35. Ridker PM, Rifai N, Lowenthal SP. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation 2001;103:1191-3. (Pubitemid 32221338)
36. Ridker PM, Danielson E, Fonseca FA, et al. JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-207.
37. Anon. Package insert. Lipitor (atorvastatin). New York:Pfizer, November (revised) 2007.
38. Raggi P, Davidson M, Callister TQ, et al. Aggressive versus moderate lipid-lowering therapy in hypercholesterolemic postmenopausal women: Beyond Endorsed Lipid Lowering with EBT Scanning (BELLES). Circulation 2005;112:563-71. (Pubitemid 41060797)
39. Newman CB, Palmer G, Silbershatz H, et al. Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients. Am J Cardiol 2003;92:670-6. (Pubitemid 37103016)
40. Nissen SE, Tuzcu EM, Schoenhagen P, et al. REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004;291:1071-80.
41. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504. (Pubitemid 38477774)
42. Arad Y, Spadaro LA, Roth M, et al. Treatment of asymptomatic adults with elevated coronary calcium scores with atorvastatin, vitamin C, and vitamin E:the St. Francis Heart Study randomized clinical trial. J Am Coll Cardiol 2005;46:166-72. (Pubitemid 40905146)
43. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39.